Page 2 - Indian Pharma Companies

Boehringer Ingelheim obtains ad-interim injunctions on 4 Indian pharma cos

The firms had launched generic versions of Boehringer's patent-protected drug Linagliptin, which is marketed under the brand name Trajenta

Near-term growth issues and cost pressure could impact Aurobindo Pharma

While valuations are now attractive, product approvals and progress on the injectable guidance are among key long-term term triggers

Caring for patients runs in our DNA, say Cipla's Samina Hamied, Umang Vohra

'Cipla has so many capabilities that for anything we need to do, we say we can do it'

Dip in demand for Covid medicines takes a toll on drug sales in March

Covid related drugs contributed 40% of the pharma market last year

India's major drug players bet on new brand launches, shows data

Industry insiders say brand launches are the lifeline of the pharma industry, and ensure steady volume growth and market share

Alembic Pharma targets 10-12 product filings from Karkhadi facility

Resolution of the observations made by the USFDA (for which Alembic has already responded to the regulator) is critical for Alembic's US business

Strong specialty sales and volumes keep it sunny for Sun Pharma

Rerating on the cards; the domestic business is expected to outperform

Wockhardt sets issue price at Rs 225/share for Rs 748-cr rights issue

Earlier in January this year, Wockhardt's board had approved raising of up to Rs 1,000 crore through a rights issue to its existing shareholders

BDR Pharma introduces prostate cancer drug with enhanced strength

The company has introduced the medication, under the brand name BDENZA 160mg, at Rs 6,300 for a strip of seven tablets

Russia-Ukraine crisis: Indian pharma exporters in wait and watch mode

An official of Dr Reddy's Laboratories said they are closely monitoring the developments and ensuring the well-being of their staff in that region is the first and foremost priority

Pharma company Venus Remedies joins AMR Industry Alliance

AMR Industry Alliance is the largest private-sector coalition working towards curbing AMR through a coordinated and multipronged response

Demand tonic to spur pharma growth in FY22: A CRISIL analysis

But exports to stay under the weather; credit outlook remains stable

AIMIL Pharma launches ayurveda-based beauty product

The product -- Ayouthveda -- has been prepared by adding time-tested herbs

Aurobindo Pharma Q2 net profit declines nearly 14% to Rs 697 crore

The drug firm on Monday reported a decline in its consolidated net profit

Cipla posts 7% year-on-year rise in Q2 PAT, riding on 10% revenue growth

Sequentially, however, the company has posted muted growth-revenue growth of 0.3%, and a PAT decline of 0.5%. Ebitda dipped sequentially too, by 9%

Back to old normal: Pharma industry returns to pre-pandemic growth level

In this first instalment of a four-part series on how some of the defining numbers in key sectors are springing back to the pre-pandemic level, Sohini Das looks at India's pharmaceutical sector

PharmEasy acquires Medlife, becomes India's largest e-pharma company

As Medlife discontinues operations, its users will move seamlessly to Pharmeasy, which will now serve 2 million households every month

Covid-19 crisis: Pharma majors step up support to affected employees

A company spokesperson said this benefit will be over and above the existing group term insurance

Covid-19: Remdesivir production scaled up to 11.9 million vials per month

All seven domestic licensed manufacturers of Remdesivir have scaled up production from 3.8 million vials per month to nearly 11.9 million vials per month, following government directives

Dr Reddy's Laboratories consolidated net profit dips 29% to Rs 557 crore

Dr Reddy's Laboratories on Friday reported 29 per cent decline in consolidated net profit at Rs 557 crore for the fourth quarter ended March 31, 2021. The Hyderabad-based drug major had posted a net profit of Rs 781 crore in January-March period of 2019-20. Net sales however rose to Rs 4,608 crore in the quarter under review as compared with Rs 4,336.1 crore in the fourth quarter of 2019-20, Dr Reddy's Laboratories said in a regulatory filing. For 2020-21 fiscal year, the company posted a consolidated net profit of Rs 1,952 crore as against Rs 2,026 crore in 2019-20. Net sales increased to Rs 18,420 crore during the last fiscal year as compared with Rs 16,357 crore in 2019-20. "In FY 21, we continued to grow across all our businesses, enhance productivity and strengthen our development pipeline," Dr Reddy's Laboratories Co-Chairman and MD G V Prasad said. The company is prioritising its efforts to launch Sputnik V vaccine across India while working on the development and ...